The ribosome is a molecular machine responsible for protein synthesis and a major target for small-molecule inhibitors. Compared to the wealth of structural information available on ribosome-targeting antibiotics in bacteria, our understanding of the binding mode of ribosome inhibitors in eukaryotes is currently limited. Here we used X-ray crystallography to determine 16 high-resolution structures of 80S ribosomes from Saccharomyces cerevisiae in complexes with 12 eukaryote-specific and 4 broad-spectrum inhibitors. All inhibitors were found associated with messenger RNA and transfer RNA binding sites. In combination with kinetic experiments, the structures suggest a model for the action of cycloheximide and lactimidomycin, which explains why lactimidomycin, the larger compound, specifically targets the first elongation cycle. The study defines common principles of targeting and resistance, provides insights into translation inhibitor mode of action and reveals the structural determinants responsible for species selectivity which could guide future drug development.
In all living cells, ribosomes are large ribonucleoprotein assemblies responsible for the accurate conversion of the genetic information encoded within mRNA into a corresponding protein. Although core functions of the ribosome are conserved in all kingdoms of life, eukaryotic ribosomes are at least 40% larger than their bacterial counterparts with a total mass ranging from ,3.3 MDa (yeasts and plants) up to ,4.5 MDa (mammals) [1] [2] [3] . The additional complexity of the eukaryotic ribosome structure is reflected in differences in terms of functions and aspects of translation and its regulation 4 . Given the central role of the ribosome in the cell, living organisms have elaborated defence strategies using small-molecule inhibitors to impair ribosomal functions. Decades of studies have revealed the great diversity of molecular mechanisms used by a multitude of antibacterial agents (antibiotics) 5, 6 . Atomic structures of prokaryotic ribosomes provided the basis for the development of novel antibiotics and in turn ribosome inhibitors served as tools to study protein synthesis in bacteria 7 . Similarly, the eukaryotic ribosome is a major target for broad-spectrum and eukaryote-specific small-molecule inhibitors isolated from natural sources. Despite limited understanding of their molecular mechanism, eukaryote-specific ribosomal inhibitors are increasingly used in research and hold potential for new therapeutics against a wide range of infectious diseases, cancers and genetic disorders [8] [9] [10] [11] [12] .
To date, no structural data are available for small-molecule inhibitors in complexes with either the complete eukaryotic ribosome or its subunits. Some eukaryote-specific inhibitors were investigated using crystals of the 50S subunit of the archaea Haloarcula marismortrui given its similarity with some parts of the eukaryotic ribosome 13, 14 . A previous X-ray study of the large subunit of Tetrahymena thermophila did not succeed to unambiguously place cycloheximide in its density due to limited resolution 15 . To gain insight into the mode of action of ribosome inhibitors in eukaryotes and to identify principles for drug development, we determined 16 crystal structures at high resolution, up to 2.9 Å , of the S. cerevisiae 80S ribosome in complexes with 12 eukaryote-specific and 4 broad-spectrum inhibitors ( Table 1 ). The broad-spectrum inhibitors target the peptidyl transferase centre on the large subunit (blasticidin S), the decoding centre (geneticin G418) and the mRNA-tRNA binding site on the small subunit (pactamycin, edeine). Eukaryotic-specific inhibitors were chosen on the basis of their capacity to alter cell proliferation and/or protein synthesis and their selectivity restricted to eukaryotes. The list comprises cycloheximide, lactimidomycin, phyllanthoside, T-2 toxin, deoxynivalenol, verrucarin A, narciclasine, lycorine, nagilactone C, anisomycin, homoharringtonine and cryptopleurine.
The present study illustrates the chemical diversity of the smallmolecule inhibitors targeting the eukaryotic ribosome. All of them were systematically found in a clash with or in a close proximity to mRNA or transfer RNA (tRNA) binding sites on both subunits (Fig. 2a, b) . In contrast to bacterial antibiotics, none were located in the peptide exit tunnel, which correlates with the increased number of rRNA modifications in this region of the eukaryotic ribosomes 16 . Although the 80S ribosome contains 1.4 MDa of additional features absent in bacteria, it is noteworthy that all eukaryote-specific inhibitors target primary functional sites. This observation highlights the role of nucleotide substitutions in the formation of eukaryotic-specific pockets in the core of the machinery. Remarkably, the structures also explain the predominance of resistance mutations found in ribosomal proteins in or near the inhibitor binding sites (Extended Data Table 2 ). In contrast to bacteria, the high-copy number of rDNA in eukaryotic genomes limits the appearance of point mutations in rRNA. Instead, resistance mutations emerge exclusively within ribosomal proteins, encoded by one or two genes, sometimes located further away and separated by a layer of rRNA nucleotides like in the case of protein uL3. Consequently, development of drugs targeting the eukaryotic ribosome can be facilitated to prevent drug resistance by focusing on regions with the smallest number of proteins.
The glutarimide inhibitors, cycloheximide and lactimidomycin, were located in the E-site on the large subunit in a pocket formed by universally conserved nucleotides of the 25S rRNA and a stretch of the eukaryote-specific protein eL42 (Fig. 3a) . Lactimidomycin bears an additional lactone ring that is positioned on top of eL42 and directed towards the subunit interface. Although chemically unrelated to glutarimides, phyllanthoside makes contact with the same rRNA nucleotides and interacts with eL42 in a manner resembling the tRNA 18, 20 . Homoharringtonine is a marketed drug for the treatment of chronic myeloid leukaemia 37 . Lycorine and narciclasine are alkaloids known for their medicinal and toxic properties 38 . T-2 toxin, deoxynivalenol and verrucarin A are widespread mycotoxins representatives of the three major trichothecenes subclasses 39 . The aminoglycoside geneticin (G418) promotes the read-through of premature termination codons 
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CCA-end (Fig. 3b) . The electron density suggests the presence of a covalent bond between C2764 (C2394, Escherichia coli numbering) and phyllanthoside epoxide group. This observation is consistent with the described irreversible effect of the inhibitor on protein synthesis 17 . The strict selectivity of E-site inhibitors towards eukaryotes is explained by the presence of two bacterial-specific rRNA residues that occlude the binding pocket (Fig. 3c) . In archaea, the orientation of the protein eL42 on the large subunit of H. marismotui would most probably preclude the binding of lactimidomycin and phyllanthoside (Extended Data Fig. 4 ). To localize the position of the E-site tRNA on the large subunit, we solved the structure of the yeast ribosome in complex with the tri-nucleotide CCA that mimics the acceptor end of the deacylated tRNA (Extended Data Fig. 5 ). The structures explain previous biochemical data showing that cycloheximide and lactimidomycin compete with the binding of the tRNA CCA-end in the E-site of the large subunit 18 ( Fig. 3d) . Phyllanthoside probably has a similar mode of inhibition 17 .
60S E-site accessibility for inhibitors
Although cycloheximide and lactimidomycin bind to the same site and probably compete with the E-site tRNA, they affect translation in a different way. Lactimidomycin preferentially arrests ribosomes at the first peptide bond, whereas cycloheximide stalls ribosomes during ongoing translation [18] [19] [20] . To better understand this difference, we used a rapid kinetic approach to study the effects of both inhibitors on tRNA binding to the E-site with a fluorescently labelled tRNA (proflavin (Prf) tRNA Phe ) 21 . Binding of tRNA Phe (Prf) to the 80S or 70S ribosomes resulted in an almost identical rapid fluorescence change, reflecting the recruitment of the tRNA to the E-site, whereas transition from the E-site to the P-site was slow and not monitored (Extended Data Fig. 6a ) 22 . When the ribosomes were pre-treated with lactimidomycin or cycloheximide, the rate of tRNA binding decreased, as expected for competitive inhibition (Fig. 3e ). The apparent rates of tRNA binding decreased with the inhibitor concentration with a dose response curves, yielding K i 5 2.7 6 0.7 mM for lactimidomycin and K i 5 0.1 6 0.05 mM for cycloheximide (Extended Data Fig. 6b ). Although the value for lactimidomycin was in agreement with the published data, cycloheximide appeared to have a much higher efficacy than reported for mammalian ribosomes using a footprinting technique 18 . Direct measurements of the binding affinity of cycloheximide to yeast ribosomes using isothermal titration calorimetry yielded a K d 5 0.14 6 0.05 mM, in agreement with the result of our competition studies (Extended Data Fig. 6c ).
Next, we tested whether the accessibility of the E-site plays a role. We followed the dissociation of tRNA Phe (Prf) from 80S ribosomes upon addition of cycloheximide or lactimidomycin (Fig. 3f ). Upon addition of cycloheximide, tRNA Phe (Prf) was rapidly removed from the E-site, indicating that the inhibitor can rapidly exchange with tRNA. In contrast, lactimidomycin did not induce tRNA dissociation, suggesting that its binding to 80S ribosomes is inhibited when the E-site is occupied by deacylated tRNA. Clearly, tRNA Phe (Prf) can un-bind from the E-site within the observation time; however, its re-binding appears to be faster than the accommodation of lactimidomycin in the E-site. The structure of lactimidomycin with its additional lactone ring may obstruct the binding of the inhibitor to the E-site, making lactimidomycin a 'slow' inhibitor that can efficiently bind only in the absence of the physiological competitor, that is, during the first elongation cycle. Our data demonstrate that the size of the glutarimide compounds dictates their accessibility to the ribosome and consequently their mode of action.
The peptidyl transferase centre
Targeted by the majority of antibiotics, the catalytic centre of the ribosome located on the large subunit is exclusively composed of highly conserved rRNA nucleotides. The reaction of peptide bond formation requires the two substrates, that is, aminoacyl-tRNA and peptidyl-tRNA, to be properly aligned in the A-site and P-site of the peptidyl transferase centre, respectively.
In contrast to blasticidin S which binds in the P-site of the large subunit in the same way in bacteria and archaea, numerous eukaryotespecific inhibitors were found associated with the A-site of the peptidyl transferase centre (Fig. 4a and Extended Data Fig. 7 ) 23 . Remarkably, chemically diverse inhibitors share a similar mode of binding within the pocket. Upon binding, all A-site inhibitors induce a similar pattern of structural rearrangements in their direct vicinity that propagate up to 15 Å away from the peptidyl transferase centre (Extended Data  Fig. 8a ). The common structural scaffold of trichothecenes inhibitors, represented by T-2 toxin, deoxynivalenol and verrucarin A, mediates all major contacts with rRNA residues in the binding pocket (Fig. 4b) . The acetate-based substituents of T-2 toxin are pointing towards the peptide tunnel entrance, whereas the verrucarin A large macrocycle extends further towards the macrolide binding site in bacteria. Lycorine, narcilasine and homoharringtonine are plant alkaloids sharing similarities, including a dioxol-pyrroline group (Fig. 4c) . In contrast to trichothecenes, the three alkaloids adopt a distinct conformation in the pocket where the dioxol-pyrroline group is positioned differently. These findings suggest that the dioxol-pyrroline group might play a specific role such as being a recognition motif for enzymes in the alkaloid ARTICLE RESEARCH biosynthetic pathway. Nagilactone C shares all the features of A-site inhibitors (Fig. 4d) . Finally, homoharringtonine and anisomycin binding is conserved between archaea and eukaryotes; however, some variations were found in the anisomycin vicinity (Extended Data Fig. 8b) .
Consistent with structural data obtained from the archaeal 50S subunit, the identity of 25S rRNA residue 2397 (2055) is suggested to influence the conformation of U2873 (U2504) that dictates the binding of either bacterial-specific or eukaryotic-specific inhibitors (Fig. 4e) 
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. In bacteria, the residue 2397 (2055) is a cytosine, whereas an adenine is found in 96% of eukaryotes. Of therapeutic interest, the remaining 4% of eukaryotes might be sensitive to antibacterial drugs instead of eukaryotic inhibitors, such as Giardia species 24 . Most A-site inhibitors were found to impair peptide bond formation during translation elongation (Extended Data Table 1 ). Superimposition of aminoacyl-tRNA structures shows that the entrance of the amino acid moiety in the peptidyl transferase centre is hindered by the presence of A-site inhibitors (Fig. 4f) .
The decoding centre
The decoding centre of the ribosome forms a geometrically restricted pocket that accurately selects aminoacyl-tRNA in accordance with mRNA codons positioned in the A-site 25, 26 . In bacteria, aminoglycosides antibiotics alter translation accuracy and inhibit tRNA translocation by perturbing the conformation of the decoding centre nucleotides. Besides their potent activity against Gram-negative bacteria, the aminoglycoside-induced suppression of premature termination holds potential for the treatment of inherited disorders caused by nonsense mutations 11, 27 . The canonical aminoglycoside binding site is located within the internal loop of helix 44 of 18S rRNA, which is part of the decoding centre that contains the essential and universally conserved nucleotides A1755 (A1492) and A1756 (A1493). In close vicinity, two nucleotides differ between bacteria and eukaryotes, but are identical in yeast and humans: G1645 (A1408) and A1754 (G1491) (Fig. 5a ) 28, 29 . The large class of aminoglycosides can be divided in three subgroups according to their chemical structures: kanamycins, neomycins and gentamicins 30 . We chose geneticin (G418) as a representative of kanamycins with high affinity for the eukaryotic ribosome. Geneticin binds into the aminoglycoside pocket and induces the flipping out of A1755 and A1756 (Fig. 5b) . The structure highlights direct interactions between geneticin ring I and the eukaryote-specific residues G1645 and A1754. a, Blasticidin S binds to the 60S tRNA P-site, whereas T-2 toxin, deoxynivalenol, verrucarin A, lycorine, narciclasine, homoharringtonine, nagilactone C and anisomycin are clustered in the 60S tRNA A-site. b, Binding site of T-2 toxin (green), deoxynivalenol (orange) and verrucarin A (cyan). c, Binding site of narcilasine (purple), lycorine (blue), homoharringtonine (pale cyan). The arrows highlight the location of the dioxol-pyrroline group. d, Binding site of nagilactone C (blue). e, The conformation of U2504 in bacteria (PDB accession codes: 2AVY, 2AW7) closes the binding site to the eukaryotic-specific A-site inhibitors. f, A-site inhibitors hinder aminoacyl-tRNA positioning in the peptidyl transferase centre. The Phe-tRNA structures were taken from PDB accession codes 2WDG, 2WDL. 3UZ3 ). e, Edeine adopts a different conformation on the bacterial (blue, PDB 1I95) and eukaryotic ribosome (yellow). f, Pactamycin (green) and cryptopleurine (purple) share the same binding site in the 40S E-site. Natural mutations in the C-terminal part of protein uS11 (red) confer resistance to cryptopleurine 43 . The mRNA structure was taken from PDB accession code 4KZZ.
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Although some aminoglycosides exhibit broad-spectrum activity against both bacteria and eukaryotes, most of them remain poorly or not active on eukaryotic cytosolic ribosomes. This resistance mechanism observed within the class is attributed to the aforementioned structural differences present in eukaryotes. We demonstrate that the conformation of G1645, which is different from the conformation of A1408 in bacteria, acts as a barrier on the eukaryotic ribosome by preventing the accommodation of aminoglycosides with a 69-substituent in ring I different from hydroxyl (Fig. 5c ). This finding confirms previous results on low inhibitory activity of aminoglycosides in eukaryotes 31 .
In line with this, most kanamycins and all gentamicins contain an amino group or a carbon side chain at this position responsible for their limited effect on the eukaryotic ribosome. However, some members of the neomycin family, such as paromomycin, contain a 69-hydroxyl substituent and yet remain poorly active on the cytosolic eukaryotic ribosomes. We identified a second structural barrier to neomycin binding: in comparison to bacteria, A1754 is shifted in eukaryotes due to a non-canonical interaction with C1646. Consequently, A1754 prevents the accommodation of the 599-hydroxyl group in ring III sometimes present in neomycins, which provides an explanation for the biochemical data (Fig. 5d) 
.
The mRNA and tRNA binding sites Additional rRNA elements and proteins have led to important remodelling of the small subunit structure in eukaryotes, which serves as a platform for numerous protein factors and participates actively in translation initiation. During initiation, the subunit binds to and moves along the mRNA 59 untranslated region to search for the proper start codon.
In bacteria, edeine binds between the P-site and the E-site of the small subunit and impairs the binding of initiator tRNA to the P-site during initiation 32, 33 . In the yeast ribosome, edeine binds to the same region but adopts a markedly different conformation than on the bacterial 30S subunit (Fig. 5e) . Located almost exclusively in the E-site, the binding pocket is formed by 18S rRNA nucleotides positioned in the mRNA path. Edeine affects translation differently in prokaryotes and eukaryotes in keeping with the fact that the mechanism of initiation is markedly distinct. Indeed, edeine interferes with start codon recognition by promoting continuous scanning of the 40S subunit and preventing subunit joining 34 . Thus, mRNA and edeine may simultaneously bind to the 40S subunit to promote scanning and prevent initiator tRNA interaction with the start codon.
Pactamycin and cryptopleurine are located exclusively in the 40S E-site and share the same binding pocket that overlaps in part with the edeine binding site. Both inhibitors are found in the mRNA channel in the E-site and interact with the ribosome by stacking with the residue G904 of 18S rRNA (Fig. 5f ). Pactamycin is a broad-spectrum inhibitor with binding mode conserved in bacteria and eukaryotes. On the other hand, cryptopleurine was described as a eukaryote-specific inhibitor 35 . The structure of cryptopleurine bound to yeast ribosome in the present functional state does not provide the basis for its specificity. The location of pactamycin and cryptopleurine imply that they act on the step of translocation from the P-site to the E-site and may also affect initiation in eukaryotes. It remains to be shown whether the translocation inhibition is promoted by hindering mRNA and/or tRNA movement.
Conclusions
This study provides a complete atomic description of 16 inhibitors bound to the yeast ribosome, highlighting common principles of targeting and shedding light on their binding sites, modes of action, determinants of species selectivity and resistance. By targeting exclusively mRNA and tRNA binding sites on both subunits, small-molecule inhibitors impair several ribosome functions mainly, but not exclusively, during the elongation cycle (Fig. 6 ).
In conjunction with kinetic experiments, we demonstrate that the size of glutarimide inhibitors dictates their binding to the ribosome at specific stages of elongation, resulting in different effects on translation. This model may have direct implications for other ribosome inhibitors in eukaryotes and in bacteria. For example, in the peptidyl transferase centre A-site, a similar mechanism may explain why anisomycin (small) and homoharringtonine (large) share the same binding site but block different stages of elongation 36 . Similarly to antibiotics acting against the bacterial ribosome, 80S ribosome inhibitors are sophisticated tools to study protein synthesis in eukaryotes 20 . Our study highlights general principles for drug targeting and provides foundations for structure-based drug design. These structures will facilitate the development of next-generation antibiotics with reduced adverse effects and new therapeutics against infectious diseases, cancers and genetic disorders caused by premature termination codons [8] [9] [10] [11] [12] . High-resolution X-ray crystallography of the 80S ribosome opens a new area of investigation-a large number of ribosome inhibitors certainly remain to be discovered and analysed.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Reagents. Lactimidomycin was provided by Jon Liu (Johns Hopkins Medical Institute), edeine by Daniel Wilson (Gene Center Munich) and T-2 toxin by Paul Hazendonk (Agriculture and Agri-Food Canada). Lycorine, homoharringtonine and narciclasine were ordered from Santa Cruz Biotech. Anisomycin, pactamycin, blasticidin S, cycloheximide, geneticin (G418), verrucarin A and deoxynyvalenol were obtained from Sigma-Aldrich. Cryptopleurine, nagilactone C and phyllanthoside were provided by NIH/NCI Developmental Therapeutics Program. When not soluble enough in water, compounds were dissolved in DMSO to achieve high concentration for stock solutions. The CCA tri-nucleotide sample was purchased from Dharmacon Thermo Scientific. Ribosome purification, crystallization and data collection. 80S ribosomes from the yeast S. cerevisiae were purified and crystallized as previously described 1 . The 80S ribosome complexes with cycloheximide and lactimidomycin were obtained by incubating vacant 80S ribosomes with 20-fold excesses of each of these compounds respectively (30 mM final concentration) for 15 min at 30uC prior to crystallization. All other ribosome-inhibitor complexes and the CCA complex were formed by soaking 80S ribosome crystals with 0.3-0.7 mM of each inhibitor for 2 h at 4uC. Data collection was performed at SOLEIL synchrotron, beam line PROXIMA1. We applied the data collection strategy previously described 1, 44 , attenuating the beam to 20% of the incoming photon flux and collecting highly redundant data when possible. Diffraction data were reduced using the XDS suite 45 .
Structure determination, refinement and analyses. The structures were solved by molecular replacement using the deposited 80S ribosome structure (PDB 3U5B-3U5I) as search model and then subjected to refinement using Phenix.refine 46 . The electron density was manually inspected to search the density corresponding to the inhibitors. Coordinates and restraints for each inhibitor were generated online with the Grade web server (Global Phasing, http://grade.globalphasing.org) using SMILES strings from PubChem database 47 . Ligands fitting and remodelling of ribosomal binding sites were performed manually using Coot 48 . Final refinement was performed with Phenix.refine. Crystallographic statistics are reported in Supplementary Information Table 1 . Ligands geometry was validated with the software Mogul from the CCDC package 49 . Drawing of chemical structures was performed with MarvinSketch suite (ChemAxon, http://www.chemaxon.com/) and figures of structures were prepared using PyMOL 1.5 (Schrödinger, http://pymol.org/). Ribosomal proteins were named throughout the manuscript according to the newly established nomenclature 50 . Rapid kinetic methods. Fluorescence experiments were carried out in buffer A (50 mM Tris-HCl, pH 7.5, 70 mM NH 4 Cl, 30 mM KCl and 20 mM MgCl 2 , 1 mM DTT) at 20uC using a stopped-flow apparatus (SX-20MV; Applied Photophysics). Proflavin fluorescence was excited at 470 nm and detected after passing a KV500 cut-off filter (Schott). Equal volumes of ribosomes (0.4 mM) and tRNA Phe (Prf) (0.15 mM) were rapidly mixed and the fluorescence change was monitored over time. Experiments in the presence of inhibitors (lactimidomycin or cycloheximide) were performed at different concentrations of inhibitor as indicated. Complexes for chase experiments were prepared by incubating fluorescence-labelled tRNA (0.15 mM) with ribosomes (0.4 mM) for 1 min at 4uC. The dissociation of tRNA Phe (Prf) from ribosomes was induced by addition of excess non-labelled tRNA Phe (20 mM), lactimidomycin (15 mM) or cycloheximide (500 mM). Time courses were evaluated using TableCurve software by single-exponential fitting, yielding k app values. The dependence of k app values on inhibitor concentrations were fitted to hyperbolic functions. Average k app values and standard deviations were obtained from at least seven time courses. Isothermal titration calorimetry. Experiments were carried out using a MicroCal ITC200 instrument (MicroCal, LLC, Northampton, MA) in buffer (20 mM HEPES, pH 7.5, 30 mM KCl, 70 mM NH 4 Cl, 7 mM MgCl 2 ). Two-microlitre aliquots of cycloheximide (70 mM stock solution) were injected into the 0.2-ml cell containing the solution of 80S ribosomes (3.7 mM). The resulting titration curves were fitted using MicroCal Origin software.
